A Director at Momenta Pharma is Exercising Options


Today it was reported that a Director at Momenta Pharma (MNTA), James Sulat, exercised options to buy 10,000 MNTA shares at $8.85 a share, for a total transaction value of $88.5K. The options were close to expired and James Sulat retained stocks.

Following this transaction James Sulat’s holding in the company was increased by 25.17% to a total of $598.8K. In addition to James Sulat, one other MNTA executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Currently, Momenta Pharma has an average volume of 356.5K.

Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $26.67, reflecting a 126.0% upside.

The insider sentiment on Momenta Pharma has been positive according to 100 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

James Sulat’s trades have generated a -12.6% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts